S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
Nov 3, 2022
11:05
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.
OncLive® On Air